China
Africa
Explore chapters and articles related to this topic
Sulfacetamide
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Sulfacetamide is a synthetic sulfonamide antibiotic with bacteriostatic activity. It inhibits bacterial folic acid synthesis by competing with p-aminobenzoic acid. With broad-spectrum activity against most gram-positive and many gram-negative organisms, it is used as an anti-infective topical agent to treat skin infections, bacterial vaginitis, keratitis, acute conjunctivitis, and blepharitis and as an oral agent for treating urinary tract infections. In pharmaceutical preparations, sulfacetamide is employed as sulfacetamide sodium (CAS number 127-56-0, EC number 204-848-4, molecular formula C8H9N2NaO3S) (1).
Sulfonamides
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
Natasha E. Holmes, M. Lindsay Grayson
Topical sulfacetamide has been used for the treatment of mild to moderate inflammatory acne vulgaris and other facial dermatoses (Thiboutot, 2000; Feldman et al., 2004; Del Rosso, 2008; Draelos, 2010). Previously it had frequently been combined with sulfur and alcohol (which can lead to poor tolerance and local irritability), but there are preparations of 10% sulfacetamide available. It is also efficacious in other dermatological conditions such as rosacea (Margolis, 2005; Torok et al., 2005; Nally and Berson, 2006; Goldgar et al., 2009), seborrheic dermatitis (Tuzun et al., 2014), and dandruff (Gupta and Nikol, 2004). There have been several case reports of poor tolerance of sulfur-based sunscreen (Torok et al., 2005).
Emerging topical drugs for the treatment of rosacea
Published in Expert Opinion on Emerging Drugs, 2021
Federica Dall’Oglio, Maria Rita Nasca, Giuseppe Micali
Sodium sulfacetamide (SS) 10% lotion alone or with sulfur (SSS) 5% combinations is available as a lotion, emollient foam, cream with sun-blocking agents, cleansers, and cleansing pad (code names: 42,192–143-01). Its action is related to the antibacterial properties of sulfacetamide and to the keratolytic and anti-inflammatory action of sulfur [36]. Although limited and dated evidence supports its efficacy [32,37,38], it is especially useful in treating patients with inflammatory rosacea who have concomitant seborrheic dermatitis [39]. Common complaints include unpleasant lingering odor, contact dermatitis, irritation, and xerosis. Also, it is contraindicated in patients with a sulfonamide hypersensitivity.
Advances in pharmacotherapy for rosacea: what is the current state of the art?
Published in Expert Opinion on Pharmacotherapy, 2022
Federica Dall’Oglio, Maria Rita Nasca, Carlo Gerbino, Giuseppe Micali
Sodium sulfacetamide (SS) 10% lotion, alone or in combination with sulfur (SSS) 5% lotion, is indicated in the treatment of patients with inflammatory rosacea, especially those who have concomitant seborrheic dermatitis [67]. Its effectiveness is linked to sulfacetamide’s antibacterial activities as well as sulfur’s keratolytic and anti-inflammatory characteristics [68]. Limited and dated evidence supports its efficacy in moderate to severe facial erythema with at least five papules and/or pustules [63]. Common side effects of SSS include contact dermatitis, irritation, and xerosis. Also, it is contraindicated in patients with a sulfonamide hypersensitivity.
Difference in vasoconstrictors: oxymetazoline vs. brimonidine
Published in Journal of Dermatological Treatment, 2021
Nwanneka Okwundu, Abigail Cline, Steven R. Feldman
The Food and Drug Administration (FDA)-approved drugs for disease management of rosacea are mainly antimicrobials such as metronidazole (0.75% gel, cream and lotion), azelaic acid (15%). sodium sulfacetamide/sulfur, subantimicrobial dose doxycycline, and ivermectin. Although these treatments produce favorable effects on papules and pustules associated with rosacea, they offer no therapeutic benefit on the persistent erythema remaining after lesion clearance (1,6).